Document ID: chunk:federal_register_of_legislation:F2022C00903:front:0:p3
Version: federal_register_of_legislation:F2022C00903
Segment Type: other
Provision Reference: 
Character Range: 5917–9102

months before the clinical onset of pulmonary thromboembolism;
(4)          having heart failure or a thrombus within the right atrium or right ventricle at the time of the clinical onset of pulmonary thromboembolism;
(5)          having a malignant neoplasm at the time of the clinical onset of pulmonary thromboembolism;
(6)          having an aneurysm of a vein in the deep venous system at the time of the clinical onset of pulmonary thromboembolism;
(7)          being overweight or obese at the time of the clinical onset of pulmonary thromboembolism;
            Note: being overweight or obese is defined in the Schedule 1 - Dictionary.
(8)          having chronic obstructive pulmonary disease at the time of the clinical onset of pulmonary thromboembolism;
(9)          having sleep apnoea at the time of the clinical onset of pulmonary thromboembolism;
(10)      being pregnant within the three months before the clinical onset of pulmonary thromboembolism;
(11)      having cytomegalovirus infection of new onset within the 30 days before the clinical onset of pulmonary thromboembolism;
(12)      having infection with human immunodeficiency virus or hepatitis C virus at the time of the clinical onset of pulmonary thromboembolism;
(13)      having active tuberculosis disease within the 30 days before the clinical onset of pulmonary thromboembolism;
            Note: active tuberculosis disease is defined in the Schedule 1 - Dictionary.
(14)      having infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) within the three months before the clinical onset of pulmonary thromboembolism;
            Note: SARS-CoV-2 is the virus which causes coronavirus disease 2019 (COVID-19).
(15)      having an autoimmune disease at the time of the clinical onset of pulmonary thromboembolism;
Note: Examples of autoimmune diseases that may cause pulmonary thromboembolism include rheumatoid arthritis, polymyositis and Sjögren syndrome.
(16)      having diabetes mellitus at the time of the clinical onset of pulmonary thromboembolism;
(17)      having a hypercoagulable state as specified at the time of the clinical onset of pulmonary thromboembolism;
            Note: hypercoagulable state as specified is defined in the Schedule 1 - Dictionary.
(18)      having a kidney disease from the specified list of kidney diseases at the time of the clinical onset of pulmonary thromboembolism;
            Note: specified list of kidney diseases is defined in the Schedule 1 - Dictionary.
(19)      having implantation of an intravenous device for a continuous period of at least 24 hours within the six months before the clinical onset of pulmonary thromboembolism;
Note: Examples of implanted devices include a central venous catheter, an indwelling cardiac pacemaker and defibrillator leads.
(20)      having surgery requiring a general, spinal or epidural anaesthetic within the six months before the clinical onset of pulmonary thromboembolism;
(21)      having an injury or illness as specified within the six months before the clinical onset of pulmonary thromboembolism;
            Note: injury or illness as specified is defined in the Schedule 1 -